About Us

Consulting Services

Market Reports

News and Press

Careers

Current and forthcoming Front Line Strategic Market ReportsTM include:

 

Technology Reports

Therapeutic Reports

   

Alternative Drug Delivery Systems Series 2003 (1999)

Acute Myocardial Infarction

Biochips

Antiangiogenesis

Biodefense 2003

Antianxiety

Bioinformatics 2002 (2000) (1998)

Antidepressants

Biomarkers

Antihypertensive Therapeutics

Cellular Assays (2002)

Anti-Obesity Therapeutics

Combination Products

Autoimmune Disorders

DNA Microarrays 2001 (2000)

Cosmeceuticals

DNA, Protein, and Cellular Arrays

Diabetes Therapeutics and Diagnostics

Drug-Eluting Stents

Hepatitis C

Functional Genomics

Lung Cancer Therapeutics

Gene Therapy

Neuropathic Pain Therapeutics

Generic Biologics

Osteoporosis

In Silico Biology

Pain Management 2003 (2001) (1999)

International Pricing & Reimbursement

Psoriasis

Metabolomics

Pulmonary Drug Delivery

Microtechnologies and Miniaturization 

RX to OTC Switch

Nanobiotechnology

Sexual Dysfunction Therapeutics

Non-Array Transcriptomics

State of Pharmaceutical Industry

Novel High-Throughput Screening

Thromboembolic Disease

Nucleic Acid Testing

 

Pharmaceutical CRM

 

Pharmacogenomics 2002 (2001)

 

Proteomics 2003 (2001)

 

SiRNA

 

Structural Genomics

 

Systems Biology

Toxicogenomics

Viral Expression Systems

 

 

For your convenience you can download Acrobat Reader from here to view our PDF files.

 


Title

Description

 No. of Pages Publication Date

Price

Each listed price is for a single color hard copy only. We also offer world-wide and site licenses for digital PDFs, as well as discounts for large volume orders. Please call (650) 525-1500 x 125 for details.
Novel High-Throughput Screening

As demand for high-throughput screening (HTS) technologies expands, companies are increasing their efforts to improve existing HTS systems in terms of accuracy, throughput, and cost effectiveness. Drug development companies are using these technologies to create personalized medicine, discover biomarkers, and identify drug targets. A new approach to managing HTS data in silico through systems modeling is fueling the use of novel concepts and technologies to address this growing market.

139 pp. January 2004 $2,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Emerging Neuropathic Pain Therapeutics

Currently, neuropathic pain is managed through a combination of anticonvulsants, opioids, and various antidepressants. Yet, most therapeutics available on the market are not specifically indicated for neuropathic pain, and exhibit inadequate efficacy and adverse events profile. Therefore, many pharmaceutical companies recognize the opportunity to provide better therapeutics and the subsequent market potential. With promising clinical trial results, eleven emerging therapeutics will likely gain significant market share between 2004 and 2009.

161 pp. January 2004 $3,200
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Systems Biology

Systems biology is an emerging approach to studying the life sciences, with many cross-functional initiatives being created to fuel collaborations. Scientists and engineers are working side-by-side, using both top-down and bottom-up approaches to model biological networks and create tools to visualize and utilize entire systems of information. Ultimately, new tools will be created that will significantly reduce research and development time and costs for both small molecule drugs and biologics.

156 pp. December 2003 $2,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
International Pricing & Reimbursement

Governmental programs and private insurers in major international markets are challenged with providing adequate services for their beneficiaries despite increasing healthcare costs. As a result, healthcare providers are employing both direct and indirect measures to limit prescription drug price hikes. The seven major markets (U.S., France, Germany, Italy, Spain, UK, and Japan) profiled in the report offer different healthcare systems; however, they are embracing similar pricing and reimbursement policies to contain prescription drug costs. This report includes analysis of the country-specific reimbursement policies and price setting dynamics as well as an impact analysis of how international protocols affect U.S. pricing strategies.

137 pp. December 2003 $2,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Cellular Assays

The cellular assays market features applications designed to effectively assess cellular function and drug response. Cellular assays help researchers meet the growing need within pharmaceutical and biotechnology companies to find more efficient and robust methods for drug evaluation. This $470M market is expected to grow at a compound annual rate of approximately 8%, reaching $700M by 2009, driven by a rebound in the economy and research spending, expanded use of high content screening in drug discovery, player consolidation, and the increased use of primary cells.

133 pp. December 2003 $2,950
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Combination Products

Combination products is an emerging field with drug-eluting stents as the current leading market segment. Other products; such as wound coverings, steroid-eluting electrodes, and closed-loop glucose monitor/insulin pumps; will account for a smaller, though significant share of the 2009 market. From 2004 to 2009, the combination products market will experience moderate growth of 10% compounded annually due to increased efforts by product developers to improve upon existing devices with novel technologies and the introduction of new product classes. The worldwide market is currently at $5.92B and is expected to reach almost $9.54B by 2009.

141 pp. November 2003 $2,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Drug-Eluting Stents

Drug-eluting stents is an emerging field with several companies preparing to enter the U.S. and EU markets. From 2003 to 2010, the drug-eluting stents market will experience sizeable growth of 24% compounded annually due new entrants, increased reimbursement by third-party payers, and high adoption rates in the U.S. The worldwide market is currently at $2.1B and is expected to reach almost $6.3B by 2008. The U.S. will hold the largest market share while the rest of the world will account for 30% of sales in 2008.

140 pp. October 2003 $2,700
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Viral Expression Systems

The viral expression systems market features technologies designed to efficiently deliver genes for basic research purposes. As the technology becomes more accepted in the scientific community, an increasing number of research programs will utilize viral expression systems in their experimental work. This $4.0M market is expected to grow at an annual rate of approximately 11%, reaching almost $6.7M by 2008, driven by a rebound in the economy and research spending, technical improvements, the emergence of universal cloning systems, and growth in siRNA research.

97 pp. October 2003 $2,300
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Generic Biologics

Generic biologics is an emerging field with several companies preparing to enter the U.S. and EU markets. From 2003 to 2010, the biogenerics market will a experience sizeable growth rate of 135% annually due to expiring patents and imminent generics approval in the U.S. The worldwide market size is currently at $30M and is expected to reach almost $12B by 2010. The U.S. and the EU will be the predominant geographical areas of market expansion while the rest of the world will account for 15% of sales in 2010.

205 pp. September 2003 $3,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Toxicogenomics

The worldwide toxicogenomics market is projected to experience moderate growth over the next five years as pharmaceutical and biotechnology companies seek tools which will enable toxicity studies to help optimize the drug discovery process. According to detailed primary and secondary research, the market size is currently at $120M and is expected to grow at an annual rate of approximately 15%, reaching almost $245M by 2008. The current estimated worldwide market breakdown is: U.S. at 65%, Europe at 20%, Japan at 10%, and the rest of the world at 5%.

162 pp. September 2003 $3,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Pharmaceutical Customer Relationship Management

Pharmaceutical CRM tools are used to optimize the efficiency of the sales force and ultimately drive prescription volume. Both the CRM software solutions and hardware platforms segments will experience moderate growth rates due to continued interest from major pharmaceutical companies. The market size is currently at $455M and is expected to grow at an annual rate of approximately 6.5%, reaching almost $625M by 2008. The current estimated worldwide market breakdown is: U.S. at 60%, Europe at 30%, Japan at 8%, and the rest of the world at 2%.

160 pp. August 2003 $3,750
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Non-Array Transcriptomics

Non-array transcriptomics technologies are used for gene expression analysis for multiple applications, including drug discovery and molecular diagnostics among others. With several advanced technologies already established in the market, major players are experiencing moderate and steady growth. The market is expected to reach $245M in 2003 and will likely grow at an annual rate of approximately 14%, reaching almost $475M by 2008. The current estimated worldwide market breakdown is U.S. at 50%, Europe at 30%, Japan at 15%, and the rest of the world at 5%.

125 pp. July 2003 $3,200
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Biomarkers

Potential biomarker applications extend from drug discovery and development to diagnostic tools. Particularly, the market potential for in vitro diagnostic tools will likely increase with a growing number of potential biomarkers due to the advent of proteomics and other discovery technologies. Using Front Lines's proprietary biomarker ranking system (FLBRS™), the reportís team of consultants selected sample biomarkers from major disease areas of cardiovascular disease, cancer, Alzheimerís disease, Parkinsonís disease, rheumatoid arthritis and depression and ranked them according to their market and technical opportunities. The report also includes current trends, drivers, and challenges facing biomarker research and development for in vitro diagnostics use.

151pp. July 2003 $3,200
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
RX-to-OTC Switch

Rx-to-OTC switching is a potential strategy that can effectively protect the revenue of prescription drugs nearing patent expiration while fulfilling consumer demand for less expensive and more accessible drugs. The recent forced switch of Schering-Plough’s Claritin demonstrates the changing role of the FDA in Rx-to-OTC switching. Patent expiration, an introduction of a new drug class, and the formulation of an appropriate switch strategy are among several key issues that should be considered by drug manufactures with potential switch candidates. Using Front Line’s proprietary OTC Switching Screen (FLOSS™), the report’s team of consultants determined that despite a number of challenges, Rx-to-OTC switching is likely to expand in various therapeutic areas in the near future, particularly that of gastrointestinal conditions, allergic rhinitis, and hypertension.

151pp. May 2003 $2,500
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
DNA, Protein, and Cellular Arrays

Microarray technology provides the ability to use substrate-sample complementary binding to mass-screen chemical or biological properties, allowing for the parallel analysis of thousands of genes, protein, or tissue samples in a single assay. They are widely used for hybridization-based gene, protein, and tissue expression analysis, particularly when screening for potential therapeutic targets and determining reactions to toxins. The total market for microarrays is expected to experience strong growth to reach over $1.6B in 2008 as a result of industry consolidation, standardization of array data, establishment of robust databases, and the development of clinical diagnostics. The current estimated worldwide market breakdown is: U.S. at 65%, Europe at 25%, Japan at 10%, and the rest of the world at 5%.

225pp. May 2003 $4,900
  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Nanobiotechnology

The application of nanotechnology to the life sciences is relatively new. Academic projects far outnumber marketed products in the field. Nanomaterials such as carbon Buckyballs, dendrimers, and metal nanoparticles have begun to reach the market for pharmaceutical and diagnostic use both in vitro and in vivo. Currently available products fall into three major segments of nanobiotechnology: drug delivery, imaging agents, and biosensors. The market for nanobiotechnology has only existed for a few years, but is expected to grow rapidly to reach over $3B in 2008, reflecting growth at an annual rate of 28% worldwide. The current estimated worldwide market breakdown is: U.S. at 65%, Europe at 20%, Japan at 10%, and the rest of the world at 5%.

202pp. April 2003

$3,375

(25% off original price)

  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Pain Management 2003

More than 160 million people in the U.S. suffer from some form of chronic pain and the number will likely increase with a graying population more prone to both chronic and acute pain.  Front Line's strategic market report on pain management focuses on the status of current therapeutics along with emerging therapeutics to be introduced in the near future.  With a variety of safety, efficacy, and reimbursement issues involving current analgesics such as COX-2 inhibitors and common narcotics, the impact of the analgesics pipeline will be significant in shaping the future pain management market.  Front Line expects the market to grow at an annual rate of 10% worldwide from 2003 to 2008.  By 2008, U.S. sales are expected to account for 72% while the rest of the world will generate roughly 28% of total analgesic revenue.

315pp. April 2003

$3,675

(25% off original price)

  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     
Biodefense

For fiscal year 2003, the federal budget request designated $5.9 billion for biodefense functions.  Several billion dollars will be spent by the National Institutes of Health and the Department of Defense on research into detection technologies, improved vaccines, and new treatments for victims of biological warfare.  While technology under development holds a great deal of promise, there are significant unmet needs in the biodefense market where innovation is overdue.  Understanding those opportunities, and mechanisms for obtaining government support, are critically important for companies looking to develop technologies applicable to biodefense.

181pp. March 2003

$3,825

(25% off original price)

  Table of Contents - Sample Pages - Order Form** - Press Release      
  **Online ordering now available!      
Return to Top of Page

 

     

Anti-Obesity Therapeutics

Front Line's Emerging Anti-Obesity Therapeutics is a must read for current and future players in the prescription weight loss market space.  Obesity has risen to epidemic proportions in the United States and other developed countries, leading more people to seek therapeutic treatment.  Over 20% and 7% of the U.S. and worldwide populations, respectively, are clinically obese.  Because obesity is a poorly treated disease with a multitude of co-morbid disorders, Front Line conducted extensive analysis of the clinical outcomes and market potential of 18 emerging anti-obesity products that are expected to enter the market within the next seven years.  Detailed secondary research and several interviews contributed to the analysis and projections for this growing category.  Also included in the report is assessment of future market influences, identification of unmet needs, and evaluations of technical and market opportunities.

176pp.  March 2003

$3,147

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**- Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Proteomics

Proteomics is a technology sector that seeks to attach functional data to all the proteins in the human body. In support of that goal, technology providers have refined and integrated the most efficient methods in protein chemistry, and adapted them to high-throughput applications. Proteomics does not exist as a novel and independent branch of science, but rather represents the best way to learn the structures and functions of great numbers of proteins, which can be crucial to drug discovery and other life sciences applications. The market for proteomics technology has sustained growth for several years, and continues at an annual rate of 12% worldwide. The current worldwide breakdown is estimated for the U.S. at 45%, Europe at 40%, Japan at 10%, and the rest of the world at 5%.

195 pp.  February 2003

$3,825

(25% off original price)

 

Table of Contents - Sample Pages - Order Form** - Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

siRNA 

The discovery of siRNA promises to be a better way to perform gene suppression. Small interfering RNA (siRNA) is a 21-23 nucleotide long RNA that mediates messenger RNA (mRNA) catalysis. The validation of siRNA's role in gene suppression and its great efficacy as a tool for target validation and functional genomics, is a great leap forward for pioneers in drug discovery. The growth rate in this category is expected to increase astronomically from 2003-2008 with a compound annual growth rate of 37% worldwide. The current worldwide breakdown is estimated for the U.S. at 45%, Europe at 40%, Japan at 12% and the rest of the world at 3%.

121 pp.  February 2003

$2,963

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

State of Pharmaceutical Industry

 

Five major factors are affecting the pharmaceutical industry. Front Line's report contains exhaustive research analyzing how these factors influence the industry now and how they will affect players over the next 5-10 years. The five areas are covered as follows and include:

  1. Government Regulations - drug prices, FDA regulations, sales & marketing practices

  2. Loss of Patent Protection - patent expiration, biogenerics, legal attack of patent validity

  3. Industry Player Environment - outsourcing, M&A, spin-outs, future industry structure

  4. New Product Development - R&D, poor quality drug candidates, slow production

  5. Socio-economic Trends - greater end-user involvement, bioterrorism, epidemiology

229 pp.  February 2003

$3,375

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Pharmacogenomics

 

Pharmacogenomics studies how genetic variations among the population affect drug response. It involves the analysis of genomic data to develop new drug targets, a screening process of more efficient clinical trials and molecular diagnostic tests used to determine individualized drug responses. An application resulting from Pharmacogenomics may create personalized drugs and diagnostics to minimize adverse effects and maximize efficacy. The growth rate in this category will more than double from 2003-2008 with a compound annual growth rate of 22% worldwide. The current worldwide breakdown is estimated for the U.S. at 60%, Europe at 25%, Japan at 10%and the rest of the world at 5%.

 

183 pp. January 2003

$3,825

(25% off original price)

 

Table of Contents - Sample Pages - Order Form** - Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Sexual Dysfunction Therapeutics

 

Front Line's strategic market report provides analyses of major sexual dysfunction (SD) categories for women and men. Women's conditions include dysfunction of desire, dysfunction of arousal, dysfunction of orgasm, pain during sexual intercourse; and, men's conditions include premature ejaculation, erectile dysfunction, and other male disorders. The report reviews the market influencing factors for male and female SD conditions, critically evaluates emerging SD therapeutics, and provides in-depth analysis on the expanded indications that will affect pricing and influence practices and perceptions. The worldwide SD market is projected to gain a 25% overall compound annual growth rate (CAGR) to reach more than $5.4B by 2007. The U.S. is estimated to generate the majority of sales revenue with a total of 70% and the rest of the world at 30%.

 

234 pp. November 2002

$3,450

(25% off original price)

 

Table of Contents - Sample Pages - Order Form** - Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

 

Alternative Drug Delivery Systems Series

 

 

Polymer, Transmucosal, Transdermal, Oral Control Release, Pulmonary and Others

 

Table of Contents - Sample Pages - Order Form** - Press Release

 

527 pp. January 2003

$4,838

(25% off original price)

  **Online ordering now available!      
Section 1 - Polymer Drug Delivery Systems

 

Polymer-based drug delivery systems allow for the slow release or extended circulation of a therapeutic over a time span ranging from days to months. The systems are often implanted or injected, thus, therapy is initiated during office visits or through surgical procedures. Front Line's report delivers an extensive review of polymer delivery systems and, an in-depth analysis of the technical and market outlook. The growth rate for drug delivery systems is expected to increase 14% annually over the next five years. Worldwide market revenues are at $4.2B with the U.S. at 55%, Europe at 35% and Japan at 5%.

 

70 pp. November 2002

$1,613

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Section 2 - Transmucosal

 

Transmucosal delivery is particularly attractive because these membranes are thin and permeable allowing for the rapid uptake of a drug into the body. Transmucosal delivery systems offer several benefits over other methods of delivery that include: direct absorption, rapid onset, and lower dosage. The delivery systems are also relatively simple and are, therefore, inexpensive to produce. The growth rate for transmucosal drug delivery systems is expected to increase 11% annually through 2007. Worldwide market revenues are at $3B with the U.S. at 55%, Europe at 30% and Japan at 10%.

 

76 pp. December 2002

$1,613

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Section 3 - Transdermal

 

Transdermal systems deliver drugs through the skin into the bloodstream, making them easy to administer. Passive and active transdermal delivery systems are used to deliver medicines in even concentrations in a way that is painless and results in few adverse side effects. Front Line's market report discusses advantages, the market and offers strategic opportunities for these delivery systems. The growth rate for transdermal drug delivery systems is expected to increase 12% annually through 2007. Worldwide market revenues are at $3B with the U.S. at 56%, Europe at 32% and Japan at 7%.

 

81 pp. December 2002

$1,613

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Section 4 - Oral Control Release

 

Oral delivery is the most preferred method for the introduction of therapeutic agents.This delivery method is advantageous over traditional oral delivery because thecompound is less susceptible to gastric and hepatic degradation. Front Line's strategic market report discusses advantages, the market and reviews in-depth the strategic opportunities for these delivery systems. The growth rate for OCR drug delivery systemsis expected to increase 9% annually through 2007. Worldwide market revenues are at$21.6B with the U.S. at 60%, Europe at 25% and Japan at 10%.

 

82 pp. December 2002

$1,613

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Section 5 - Pulmonary and Others Drug Delivery Systems

 

Pulmonary delivery systems, absorption and drug deposition through alveoli in the lungs,are convenient, readily absorb fragile proteins, and deliver drugs directly to the heart forsystemic distribution. The growth rate for pulmonary drug delivery systems is expectedto increase 9% annually through 2007. Worldwide market revenues are at $7.8B with the U.S. at 47%, Europe at 34% and Japan at 10%. Other drug delivery systems include:Liposome delivery systems, vesicles composed of a phospholipid bilayer in which pharmaceutical agents can be contained, allowing controlled release, target specificity and prolonged life span of drugs. Needle-free injection systems utilize pressurized gas ora coiled spring for needle-free injection that shoots pharmaceutical agents through the skin for administration with reduced pain, less risk of cross contamination and capabilityfor mass immunization. The growth rate for other drug delivery systems is expected toincrease 20% annually through 2007. Worldwide market revenues are at $600M with the U.S. at 50%, Europe at 25% and Japan at 20%.

 

140 pp. January 2003

$1,613

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

In Silico Biology

 

In silico biology collects data from genomics, functional proteomics, expression arrays and literature, and integrates all of it into a single cohesive model that can be used to identify drug targets, predict lead compounds and the pharmacological value and behavior of those leads. While the industry is still in its infancy, a key goal is to conserve time and money by using computer models to run pilot experiments more quickly and cost-effectively than can be done in a traditional "wet lab." The ultimate goal for many is the creation of a virtual patient and, while this may be many years away, the possibilities of biology simulation are endless and have the likelihood of saving the industry years of research and millions of dollars in revenue. The growth rate in this category will more than double from 2002-2007 with a compound annual growth rate of 50% worldwide. The current worldwide breakdown is estimated for the U.S. at 70%, Europe at 20%, Japan at 5% and the rest of the world at 5%.

 

175 pp. November 2002

$3,675

(25% off original price)

 

Table of Contents - Sample Pages - Order Form** - Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Structural Genomics

 

Structural genomics involves the determination, analysis and dissemination of three-dimensional structures of macromolecules including proteins and RNA molecules. The structural view of these types of molecules will provide a better understanding of molecule functions and interactions as well as change the understanding of biological systems. The majority of research focuses on determining protein structure and function. The main platforms used for this research are NMR spectroscopy and X-ray crystallography. Front Line's report reviews the market dynamics of this high-growth area, the economic impact it will have on key players in the market and the rapidly changing technologies. The growth in this category is substantial with a total compound annual growth rate (CAGR) worldwide at 32% over the next five years and estimated revenues for the U.S. at 70% with Europe at 20% and Japan at 5%.

 

185 pp. October 2002

$3,825

(25% off original price)

 

Table of Contents - Sample Pages - Order Form **- Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Antianxiety

 

Anxiety affects more than 490 million people worldwide and is expected to continue to increase through 2007. Anxiety disorders are a medical illnesses accompanied by overwhelming anxiety and fear that include phobia, obsessive-compulsive disorder, panic disorder, post traumatic stress disorder and generalized anxiety disorder. Front Line's report reviews the market for current and emerging therapeutics found to be effective for anxiety disorders as well as the economic impact generics and emerging drugs will have on the anxiolytics market. Products dominating the market currently are the benzodiazepines, however new hormone inhibitors, such as tachykinin antagonists and GABA modulators, will further fragment the market as physicians continue to seek more efficacious drugs with fewer side effects. The total anxiolytic market is estimated to grow at an 8.0% overall compound annual growth rate (CAGR) from 2002 to 2007. By 2007 U.S. sales are expected to reach 67% while the rest of the world generates roughly 33% of total revenue.

 

206 pp. October 2002

$3,375

(25% off original price)

 

Table of Contents - Sample Pages - Order Form**- Press Release

   

 

  **Online ordering now available!      
Return to Top of Page

 

   

 

Metabolomics

 

Metabolomics is a powerful technology, especially when its data is combined with genomic and proteomic data. Together these data complement each other and can provide more information than any one set on its own. New disease markers can also be discovered using metabolomics technologies. Non-targeted approaches to metabolic profiling reveal biochemicals that were not previously identified, therefore, leading to diagnostic testing that can be developed around the findings. The metabolomics technology industry is expected to increase in size and revenue through the year 2007 to an estimated $225 million in the U.S., Europe and Japan versus $38 million this year. The compound annual growth rate for the market from 2002-2007 is 46%. This report provides market trends and evaluates this novel way of utilizing a technology that works together with current and upcoming technologies. These developing technologies have the potential of being applied in the areas of drug discovery and development, and preventive screening/diagnostics. Research continues to refine these technologies in efforts to put these applications to use as quickly as possible.

 

162 pp. September 2002

$3,713

(25% off original price)

 

Table of Contents - Sample Pages - Order Form - Press Release

   

 

Return to Top of Page

 

   

 

Antidepressants

 

Major depression affects 330 million people worldwide and is expected to increase exponentially from 2002 through 2007. While the most popular class of drugs, Selective Serotonin Reuptake Inhibitors (SSRIs), are used a majority of the time to treat depression in the U.S. and worldwide, substance P/NK1 antagonists are expected to appeal to SSRI non-responders to gain a significant part of the market by 2007. These market trends and dynamics forcing a shift in antidepressant market share are analyzed within this report. In particular, we examine the current drugs in development such as Lexapro, Cymbalta, and Vestra and predict their impact on the market. In addition, we evaluate leading business models and recommend potential business strategies for current marketers as well as new entrants to the market.

 

210 pp. August 2002

$3,375

(25% off original price)

 

Table of Contents - Sample Pages - Order Form - Press Release

   

 

Return to Top of Page

 

   

 

Microtechnologies and Miniaturization

 

Microtechnologies enable researchers to perform chemical and biological measurements rapidly in multiplexed, miniaturized, and automated format. This report investigates the current and emerging products and applications of microtechnology components, diagnostic tools and systems, within drug discovery and development and medical testing. By outlining key market drivers and bottlenecks, and forecasting market growth through 2007, this report discusses how pharmaceutical and biotechnology companies and the medical community are applying microtechnologies today, and how they might be used in 2007. This comprehensive analysis details product pipelines and corporate strategies of key participants, and provides recommendations for maintaining or expanding market share.

 

160 pp. June 2002

$2,325

(50% off original price)

 

Table of Contents - Sample Pages - Order Form - Press Release

   

 

Return to Top of Page

 

   

 

Hepatitis C

 

Hepatitis C, one of the most significant causes of chronic liver disease, has reached epidemic proportions. Almost 4 million Americans and almost 170 million people worldwide are infected with hepatitis C &endash; an overall prevalence of roughly 3.3% of the world's population. To better understand the future of this growing market, Front Line investigates current therapeutics and drugs in all stages of clinical development, highlighting the strategies and strengths of each key player. Assessing the factors driving market growth, and identifying unmet medical needs, this report provides recommendations for optimized pricing strategies and volume increases, to help current and future participants to secure their place in the market.

 

167 pp. June 2002

$2,075

(50% off original price)

 

Table of Contents - Sample Pages - Press Release 

   

 

Return to Top of Page

 

   

 

Cellular Assays (2002)

 

The use of cellular assays is becoming commonplace among researchers in pharmaceutical and biotech companies, primarily for target validation and lead identification and optimization. This analysis investigates the current and future applications of cellular assays within drug discovery, including technologies such as fluorescence, bio/ chemiluminescence, and other detection methods. Providing competitive positioning analysis and key trends, drivers and bottlenecks, this report forecasts the market size and growth rate through 2007. We offer strategic recommendations for optimizing current and future opportunities based on leading business scenarios and a thorough analysis of the continually changing industry landscape.

 

125  pp. May 2002

$2,075

(50% off original price)

 

Table of Contents - Sample Pages - Order Form - Press Release

   

 

Return to Top of Page

 

   

 

Functional Genomics

 

A comprehensive analysis on the emerging area of Functional Genomics, focusing on the available technologies and applications of the Microarray Gene Expression Technologies, Non-array Gene Expression Technologies, Knockout and Transgenic Animals and Downregulation Reagents market segments. Detailing the drivers, barriers and unmet needs impacting each market segment as well as the industry as a whole, this report provides market size and growth forecasts from 2002 through 2007, including key players and leading products in each segment. By evaluating leading business models, this report recommends deal structures and identifies strategic growth opportunities for current participants and new entrants to this market.

 

250  pp. April 2002

 $2,625

(50% off original price)

 

Table of Contents - Sample Pages - Order Form - Press Release

   

 

Return to Top of Page

 

   

 

Psoriasis

 

The overall increase in incidence and prevalence of psoriasis and the introduction of novel biologic therapies will drive the market to grow at a double-digit growth rate. This report estimates the current and future market size and company market shares through 2007, analyzing worldwide compounds currently in clinical development by region, indication and therapeutic class. In addition to detailed explanation of epidemiology and current and future treatment options for mild, moderate, and severe psoriasis, this analysis investigates treatment costs and reimbursement issues, to provide strategic recommendations for companies seeking to compete in this explosive market.

 

150  pp. April 2002

 $1,575

(50% off original price)

 

Table of Contents - Sample Pages -Order Form

     
Return to Top of Page

 

   

 

Lung Cancer Therapeutics

 

An in-depth discussion on the current and emerging therapeutics used for the treatment of small cell and non-small cell lung cancer. In addition to extensive primary and secondary research, Front Line consulted a panel of practicing Oncologists, who daily treat Lung Cancer patients, to provide foresight on therapeutic options. This report investigates key players and promising therapeutics in development, outlines differing needs of each patient population, assesses factors driving market growth, and identifies unmet needs in the market. Analyzing factors key to the success in oncology chemotherapy, this report provides recommendations for product development, product life extension, partnering and positioning strategies.

 

270  pp. March 2002

 $2,275

(50% off original price)

 

Table of Contents - Sample Pages - Brochure - Press Release

     
Return to Top of Page

 

   

 

Bioinformatics 2002

 

Bioinformatics, A Strategic Market Analysis provides an in-depth discussion of the current and emerging applications of bioinformatics to accelerate the drug discovery and development process. This report investigates issues impacting the growth of the content, software analysis and IT infrastructure market segments, and profiles the leading products and suppliers within each segment. Combing end-user and supplier insight, we identify critical factors in the internal development vs. external purchase decision process and outline strategic opportunities, empowering readers to make informed decisions as they enter or expand their business within this competitive environment.

 

250  pp. January 2002

 $1,138

(75% off original price)

 

Table of Contents - Sample Pages - Brochure - Press Release

     
Return to Top of Page

 

   

 

 

Reports from 2001 and Earlier

   

 

Front Line Strategic Consulting, 1850 Gateway Drive, Suite 600, San Mateo, CA 94404

Phone: 650-525-1500 Fax: 650-525-2727